Retinal Protection Sciences
is developing a class 2B medical device and system referred to as
first preventative and therapeutic treatment modality for the most important and widespread causes of irreversible blindness worldwide. These include age-related macular degeneration (AMD), diabetic retinopathy (DR), open angle glaucoma (OAG) and inherited retinal degenerations (IRDs) such as retinitis pigmentosa (RP). Each are forms of neurodegenerative disease, and as such, have much in common. The
believes that the future of medical care will emphasize disease prevention and functional restoration through bioactivation; activation of the body’s own mechanisms for repair. While we have powerful and highly effective systems for repair and regeneration, the key drivers of the chronic progressive diseases of ageing that plague the modern world do not engage these processes.
The ™ system is designed to activate and engage these powerful natural restorative processes safely and effectively to slow, stop, or reverse disease progression, safely improve vision, and reduce the risks of vision loss. The ™.
™ can be thought of as the therapeutic analogue of Optical Coherence Tomography (“OCT”). The ™ system can be used to treat the things that OCT can be used to diagnose, and more. Thus, just as OCT revolutionized ophthalmic diagnosis,
anticipates completion of the ™ system’s regulatory approval late in early 2020 and looks forward to providing those at risk for vision loss with this new, innovative and powerful tool.
· U.S. Patent No. 9,381,115. System and process for retina phototherapy. Filed May 12, 2012; awarded July 5, 2016.
· U.S. Patent No. 9,168,174. Process for restoring responsiveness to medication in tissues of living organisms. Filed January 25, 2015; awarded September 4, 2015
· U.S. Patent No. 9,381,116. Subthreshold micropulse prophylactic treatment for chronic progressive retinal diseases. Filed October 23, 2015; awarded July 5, 2016.
· U.S. Patent No. 9,427,602. Pulsating electromagnetic and ultrasound for stimulating targeted heat shock proteins for achieving retinal repair. Filed Oct 26, 2015; awared August 30, 2016.
· U.S. Patent No. 9,962,291. System and process for neuroprotective therapy for glaucoma. Filed: August 9, 2016, awarded May 1, 2018.
· U.S. Patent No. 10,076,671. Apparatus for retinal phototherapy, filed July 1, 2016; awarded Sept 2018.
· U.S. Patent No. 10,117,777. System for neuroprotective therapy for glaucoma. Filed Oct 24, 2916; awarded Nov 6, 2018.
· U.S. Patent No. 10,219, 947. System and process for retina phototherapy. Filed March 13, 2013; awarded March 5, 2019.
· U.S. Patent No. 10,238, 542. System and process for retinal phototherapy. Filed June 6, 2016; awarded March 26, 2019.
· U.S. Patent No. 10,278,865. Process for neuroprotective therapy for glaucoma. Filed May 3, 2016; awarded May 7, 2019.
· U.S. Patent No. 10,285,859. System for performing retinal photostimulation. Filed October 22, 2016. Issued May 14, 2019
· U.S. Patent No. 10,299,961. System for neuroprotective therapy for glaucoma. Filed April 25, 2018. Issued May 28, 2019.
Jeffrey K Luttrull, MD Founder, Chief Executive and Medical Officer
Benjamin WL Margolis, MA Chief Engineering Officer
David B Chang, PhD Chief Scientific Officer
Harry Carneal Chief of Business Development
Oculox Technologies SA Strategic Engineering and Manufacturing Partner